×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BHVN – biohaven ltd. common shares (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BHVN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/25
08:09 pm
bhvn
Mixed signals cloud the orphan drug market [Yahoo! Finance]
Medium
Report
Mixed signals cloud the orphan drug market [Yahoo! Finance]
3/23
01:42 pm
bhvn
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential [Yahoo! Finance]
Low
Report
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential [Yahoo! Finance]
3/21
08:16 pm
bhvn
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash [Yahoo! Finance]
Medium
Report
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash [Yahoo! Finance]
3/19
07:30 am
bhvn
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
Low
Report
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
3/11
10:56 am
bhvn
Biohaven (BHVN) had its price target raised by TD Cowen from $15.00 to $30.00. They now have a "buy" rating on the stock.
Low
Report
Biohaven (BHVN) had its price target raised by TD Cowen from $15.00 to $30.00. They now have a "buy" rating on the stock.
3/9
04:05 pm
bhvn
Biohaven (BHVN) had its "strong-buy" rating reaffirmed by Raymond James Financial, Inc..
Low
Report
Biohaven (BHVN) had its "strong-buy" rating reaffirmed by Raymond James Financial, Inc..
3/4
08:00 am
bhvn
Biohaven (BHVN) had its price target lowered by HC Wainwright from $11.00 to $10.00. They now have a "neutral" rating on the stock.
Low
Report
Biohaven (BHVN) had its price target lowered by HC Wainwright from $11.00 to $10.00. They now have a "neutral" rating on the stock.
3/3
05:03 pm
bhvn
Biohaven (BHVN) had its "outperform" rating reaffirmed by Leerink Partners.
Low
Report
Biohaven (BHVN) had its "outperform" rating reaffirmed by Leerink Partners.
Date
Time
Symbol
Company Name
Action
%Chg
3/2/2026
04:05 pm
bhvn
biohaven ltd. common shares
BEAT
Report
-9.7%
biohaven ltd. common shares
11/10/2025
06:58 am
bhvn
biohaven ltd. common shares
BEAT
Report
-7.7%
biohaven ltd. common shares
8/11/2025
07:00 am
bhvn
biohaven ltd. common shares
BEAT
Report
-8.2%
biohaven ltd. common shares
5/12/2025
04:05 pm
bhvn
biohaven ltd. common shares
BEAT
Report
-5.1%
biohaven ltd. common shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/19
06:18 pm
bhvn
Form 4 Biohaven Ltd. For: Mar 17 Filed by: Mehta Kishan
Low
Report
Form 4 Biohaven Ltd. For: Mar 17 Filed by: Mehta Kishan
3/13
04:55 pm
bhvn
Form DEF 14A Biohaven Ltd. For: Apr 28
Low
Report
Form DEF 14A Biohaven Ltd. For: Apr 28
3/9
06:12 pm
bhvn
Form 4/A Biohaven Ltd. For: Mar 04 Filed by: CHILDS JOHN W
Low
Report
Form 4/A Biohaven Ltd. For: Mar 04 Filed by: CHILDS JOHN W
3/3
06:09 pm
bhvn
Form 4 Biohaven Ltd. For: Feb 27 Filed by: Buten Matthew
Low
Report
Form 4 Biohaven Ltd. For: Feb 27 Filed by: Buten Matthew
3/3
06:08 pm
bhvn
Form 4 Biohaven Ltd. For: Feb 27 Filed by: Gentile Kimberly
Low
Report
Form 4 Biohaven Ltd. For: Feb 27 Filed by: Gentile Kimberly
3/3
06:08 pm
bhvn
Form 4 Biohaven Ltd. For: Feb 27 Filed by: Clark George C.
Low
Report
Form 4 Biohaven Ltd. For: Feb 27 Filed by: Clark George C.
3/3
06:08 pm
bhvn
Form 4 Biohaven Ltd. For: Feb 27 Filed by: Car Bruce
Low
Report
Form 4 Biohaven Ltd. For: Feb 27 Filed by: Car Bruce
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/16
Form DEFA14A Biohaven Pharmaceutical
14.2%
2/10 Biohaven's Rimegepant Named To Cortellis 2020 Potential Blockbuster "Drugs to Watch" List 12.9%
7/22 Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled 10.4%
9/4 Form 8-K Biohaven Pharmaceutical For: Sep 04 9.3%
2/27 Biohaven's NURTEC™ ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults 8.1%
7/15 Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The Lancet 7.6%
3/12 Form 5 Biohaven Pharmaceutical For: Dec 31 Filed by: Coric Vlad 7.2%
5/7 Form 8-K Biohaven Pharmaceutical For: May 07 6.5%
4/27 Biohaven Enters Into Agreement With Genpharm for Distribution of NURTEC™ ODT in the Middle East 5.9%
1/27 Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.7%
2/10 Biohaven's Rimegepant Named To Cortellis 2020 Potential Blockbuster "Drugs to Watch" List 12.9%
7/22 Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled 10.4%
9/4 Form 8-K Biohaven Pharmaceutical For: Sep 04 9.3%
2/27 Biohaven's NURTEC™ ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults 8.1%
7/15 Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The Lancet 7.6%
3/12 Form 5 Biohaven Pharmaceutical For: Dec 31 Filed by: Coric Vlad 7.2%
5/7 Form 8-K Biohaven Pharmaceutical For: May 07 6.5%
4/27 Biohaven Enters Into Agreement With Genpharm for Distribution of NURTEC™ ODT in the Middle East 5.9%
1/27 Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.7%
TOP News Decliners
3/31
Form 8-K Biohaven Pharmaceutical For: Mar 30
-13.6%
6/17 Biohaven Announces Proposed Public Offering Of Common Shares -12.4%
1/10 Form 4 Biohaven Pharmaceutical For: Jan 08 Filed by: Stock Elyse -11.2%
12/17 Biohaven Pharma says acute migraine treatment succeeds in study [Reuters] -10.7%
1/28 Biohaven Announces Proposed Public Offering Of Common Shares -8.8%
6/18 Biohaven Announces Pricing Of $300 Million Public Offering Of Common Shares -7.2%
12/6 Biohaven Pharma to continue late-stage study of Alzheimer's treatment [Reuters] -7.0%
4/7 Biohaven Enters Into Collaboration With Cove, Leading Migraine Telemedicine Platform, To Enhance Accessibility Of NURTEC™ ODT -5.9%
2/10 Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint -5.9%
3/30 Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC™, Dosed Every Other Day, for the Preventive Treatment of Migraine -5.0%
6/17 Biohaven Announces Proposed Public Offering Of Common Shares -12.4%
1/10 Form 4 Biohaven Pharmaceutical For: Jan 08 Filed by: Stock Elyse -11.2%
12/17 Biohaven Pharma says acute migraine treatment succeeds in study [Reuters] -10.7%
1/28 Biohaven Announces Proposed Public Offering Of Common Shares -8.8%
6/18 Biohaven Announces Pricing Of $300 Million Public Offering Of Common Shares -7.2%
12/6 Biohaven Pharma to continue late-stage study of Alzheimer's treatment [Reuters] -7.0%
4/7 Biohaven Enters Into Collaboration With Cove, Leading Migraine Telemedicine Platform, To Enhance Accessibility Of NURTEC™ ODT -5.9%
2/10 Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint -5.9%
3/30 Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC™, Dosed Every Other Day, for the Preventive Treatment of Migraine -5.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: